Warfarin response

Common Name(s)

Warfarin response

Warfarin is a widely prescribed anticoagulant for the prevention of thromboembolic diseases for subjects with deep vein thrombosis, atrial fibrillation, or mechanical heart valve replacement ({27:Yuan et al., 2005}). The dose requirement is highly variable, both interindividually and interethnically. Variation in the VKORC1 gene is believed to be the most important individual predictor of warfarin dose, accounting for about 30% of the variance observed in dosing ({17:Ross et al., 2010}).
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Warfarin response" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Warfarin response" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Warfarin response" returned 38 free, full-text research articles on human participants. First 3 results:

Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
 

Author(s): Alexander G Vandell, Joseph Walker, Karen S Brown, George Zhang, Min Lin, Michael A Grosso, Michele F Mercuri

Journal: Heart. 2017 Nov;103(22):1800-1805.

 

The aim of this study was to investigate whether genetic variants can identify patients with venous thromboembolism (VTE) at an increased risk of bleeding with warfarin.

Last Updated: 9 Jul 2017

Go To URL
Genetic determinants of variability in warfarin response after the dose-titration phase.
 

Author(s): Otito F Iwuchukwu, Andrea H Ramirez, Yaping Shi, Erica A Bowton, Vivian K Kawai, Jonathan S Schildcrout, Dan M Roden, Joshua C Denny, C Michael Stein

Journal: Pharmacogenet. Genomics. 2016 Nov;26(11):510-516.

 

Genetic factors contribute considerably toward variability in warfarin dose requirements and are important in the dose-titration phase; their effects on the stability of anticoagulation later in therapy are not known.

Last Updated: 15 Sep 2016

Go To URL
Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
 

Author(s): Jonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, Richard C Becker, G√ľnter Breithardt, Scott D Berkowitz, Jonathan L Halperin, Graeme J Hankey, Werner Hacke, Kenneth W Mahaffey, Christopher C Nessel, Daniel E Singer, Keith A A Fox, Manesh R Patel

Journal: Circulation. 2016 Jul;134(2):e7-8.

 

Last Updated: 12 Jul 2016

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Warfarin response" returned 2 free, full-text review articles on human participants. First 3 results:

Influence of CYP2C9 and VKORC1 on patient response to warfarin: a systematic review and meta-analysis.
 

Author(s): Andrea L Jorgensen, Richard J FitzGerald, James Oyee, Munir Pirmohamed, Paula R Williamson

Journal: PLoS ONE. 2012 ;7(8):e44064.

 

Warfarin is a highly effective anticoagulant however its effectiveness relies on maintaining INR in therapeutic range. Finding the correct dose is difficult due to large inter-individual variability. Two genes, CYP2C9 and VKORC1, have been associated with this variability, leading ...

Last Updated: 6 Sep 2012

Go To URL
The pharmacogenetics of the response to warfarin in Chinese.
 

Author(s): May P S Lam, Bernard M Y Cheung

Journal: Br J Clin Pharmacol. 2012 Mar;73(3):340-7.

 

Warfarin is a commonly used oral anticoagulant with a narrow therapeutic range and large interindividual variability in daily dose. Compared with Caucasians, Chinese are known to require lower doses of warfarin. Differences between Caucasians and Chinese in the allelic frequencies ...

Last Updated: 14 Feb 2012

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Genetic Variability in the Response to Warfarin at Baseline and During Induction of CYP2C9
 

Status: Not yet recruiting

Condition Summary: Healthy Subjects

 

Last Updated: 5 Jul 2011

Go to URL